Veracyte, Inc. announced that preliminary clinical data for the company’s noninvasive nasal swab test – the first of its kind – for early detection of lung cancer will be presented at the annual meeting of the American College of Chest Physicians (CHEST), being held October 18-23 in New Orleans. The presentation will highlight the early performance characteristics and intended use of the novel genomic test.
Additionally, data from five studies demonstrating the clinical performance and utility of Veracyte’s Percepta Genomic Sequencing Classifier (GSC) and Envisia Genomic Classifier – which are used to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis (IPF), respectively – will be presented during the CHEST meeting.
“We look forward to the CHEST meeting, where data from multiple studies will demonstrate our genomic tests’ ability to answer important clinical questions that inform diagnosis and treatment decisions for patients with suspected cancer or other diseases,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “This includes five studies reinforcing the value that our Percepta and Envisia genomic classifiers provide to patients with potential lung cancer and interstitial lung diseases, including IPF. We are particularly excited to share new data that demonstrate significant progress in our development of the first noninvasive nasal swab test for early lung cancer detection.”
Visit Veracyte for the release
